Basiliximab Versus Daclizumab Combined With Triple Immunosuppression in Deceased Donor Renal Graft Recipients

Transplantation Proceedings

Volumn 39, Issue 10, 2007, Pages 3093-3097

  Grego, K ^a   Arnol, M ^a   Bren, A F ^a   Kmetec, A ^a   Tomazic J ^a   Kandus, A ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CREATININE; CYCLOSPORIN A; DACLIZUMAB; DILTIAZEM; GANCICLOVIR; HLA A ANTIGEN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ADULT; AGED; ARTICLE; ASPERGILLOSIS; BASAL CELL CARCINOMA; BIOPSY; CLINICAL TRIAL; COHORT ANALYSIS; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DYSPNEA; FEMALE; GRAFT SURVIVAL; HERPES SIMPLEX; HERPES ZOSTER; HOT FLUSH; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; SEPSIS; SEPTICEMIA; SIDE EFFECT; SKIN CARCINOMA; SURVIVAL RATE; THROMBOTIC THROMBOCYTOPENIC PURPURA; URINARY TRACT INFECTION; WOUND INFECTION;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; CADAVER; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; HISTOCOMPATIBILITY TESTING; HOSPITALIZATION; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RECOMBINANT FUSION PROTEINS; SAFETY; TISSUE DONORS; TREATMENT OUTCOME;

EID: 37049002412     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2007.04.032     Document Type: Article

References (22)

1. Onrust S.V., and Wiseman L.R. Basiliximab. Drugs 57 (1999) 207
2. Maes B.D., and Vanrenterghem Y.F. Anti-interleukin-2 receptor monoclonal antibodies in renal transplantation. Nephrol Dial Transplant 14 (1999) 2824
3. Goebel J., Stevens E., Forrest K., et al. Daclizumab (Zenapax) inhibits early interleukin-2 receptor signal transduction events. Transpl Immunol 8 (2000) 153
4. Kovarik J.M., Kahan B.D., Rajagopalan P.R., et al. Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation. Transplantation 68 (1999) 1288
5. Kovarik J.M., Pescovitz M.D., Sollinger H.W., et al. Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. Clin Transplant 15 (2001) 123
6. Vincenti F., Lantz M., Birnbaum J., et al. A phase I trial of humanized anti-interleukin-2 receptor antibody in renal transplantation. Transplantation 63 (1997) 33
7. Kahan B.D., Rajagopalan P.R., and Hall M. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. Transplantation 67 (1999) 276
8. Ponticelli C., Yussim A., Cambi V., et al. A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients. Transplantation 72 (2001) 1261
9. Lawen J.G., Davies E.A., Mourad G., et al. Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation. Transplantation 75 (2003) 37
10. Kovarik J., Wolf P., Cisterne J.M., et al. Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts. Transplantation 64 (1997) 1701
11. Nashan B., Moore R., Amlot P., et al. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 350 (1997) 1193
12. Vincenti F., Kirkman R., Light S., et al., Daclizumab Triple Therapy Study Group. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 338 (1998) 161
13. Nashan B., Light S., Hardie I.R., et al., Daclizumab Double Therapy Study Group. Reduction of acute renal allograft rejection by daclizumab. Transplantation 67 (1999) 110
14. van Gelder T., Warle M., and ter Meulen R.G. Anti-Interleukin-2 receptor antibodies in transplantation. Drugs 64 (2004) 1737
15. Basadonna G.P., Matas A.J., Gillingham K.J., et al. Early versus late acute renal allograft rejection: impact on chronic rejection. Transplantation 55 (1993) 993
16. Hariharan S., Johnson C.P., Bresnahan B.A., et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 342 (2000) 605
17. Gjertson D.W. Impact of delayed graft function and acute rejection on graft survival. Transplant Proc 34 (2002) 2432
18. Pescovitz M.D., Bumgardner G., Gaston R.S., et al. Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation. Clin Transplant 17 (2003) 511
19. Kandus A., Grego K., Arnol M., et al. Effective immunoprophylaxis with basiliximab plus triple therapy in renal transplantation: five-year single-center experience. Transplant Proc 38 (2006) 2853
20. Khan A.J., Sarkissian N., Brennen S.T., et al. Comparison of two IL-2 receptor blockers in decreasing the incidence of acute rejection in early post-transplant time in renal transplant recipients. J Am Soc Nephrol 11 (2000) 694A
21. Nair M.P., Nampoory M.R.N., Johny K.V., et al. Induction immunosuppression with interleukin-2 receptor antibodies (basiliximab and daclizumab) in renal transplant recipients. Transplant Proc 33 (2001) 2767
22. Opelz G., and Dohler B. Cyclosporine and long-term kidney graft survival. Transplantation 72 (2001) 1267